Literature DB >> 17228862

Isothiazoloquinolones with enhanced antistaphylococcal activities against multidrug-resistant strains: effects of structural modifications at the 6-, 7-, and 8-positions.

Qiuping Wang1, Edlaine Lucien, Akihiro Hashimoto, Godwin C G Pais, David M Nelson, Yongsheng Song, Jane A Thanassi, Christopher W Marlor, Christy L Thoma, Jijun Cheng, Steven D Podos, Yangsi Ou, Milind Deshpande, Michael J Pucci, Douglas D Buechter, Barton J Bradbury, Jason A Wiles.   

Abstract

We describe the biological evaluation of isothiazoloquinolones (ITQs) having structural modifications at the 6-, 7-, and 8-positions. Addition of a methoxy substituent to C-8 effected an increase in antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA) and a decrease in cytotoxic activity against Hep2 cells. Removal of fluorine from C-6 or replacement of the C-8 carbon with a nitrogen compromised anti-MRSA activity. When the groups attached at C-7 were compared, the anti-MRSA activity decreased in the order 6-isoquinolinyl > 4-pyridinyl > 5-dihydroisoindolyl > 6-tetrahydroisoquinolinyl. The compound with the most desirable in vitro biological profile was 9-cyclopropyl-6-fluoro-8-methoxy-7-(2-methylpyridin-4-yl)-9H-isothiazolo[5,4-b]quinoline-3,4-dione (7g). This ITQ demonstrated (i) strong in vitro anti-MRSA activity (MIC90 = 0.5 microg/mL), (ii) strong inhibitory activities against S. aureus DNA gyrase and topoisomerase IV, with weak activity against human topoisomerase II, (iii) weak cytotoxic activities against three cell lines, and (iv) efficacy in an in vivo murine thigh model of infection employing MRSA.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17228862     DOI: 10.1021/jm060844e

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  10 in total

1.  In vitro activity of ACH-702, a new isothiazoloquinolone, against Nocardia brasiliensis compared with econazole and the carbapenems imipenem and meropenem alone or in combination with clavulanic acid.

Authors:  Lucio Vera-Cabrera; Mayra Paola Campos-Rivera; Wendy G Escalante-Fuentes; Michael J Pucci; Jorge Ocampo-Candiani; Oliverio Welsh
Journal:  Antimicrob Agents Chemother       Date:  2010-03-22       Impact factor: 5.191

Review 2.  Molecular epidemiology of clinically significant antibiotic resistance genes.

Authors:  P M Hawkey
Journal:  Br J Pharmacol       Date:  2008-03       Impact factor: 8.739

3.  Synthesis and evaluation of 1-cyclopropyl-2-thioalkyl-8-methoxy fluoroquinolones.

Authors:  Kevin R Marks; Muhammad Malik; Arkady Mustaev; Hiroshi Hiasa; Karl Drlica; Robert J Kerns
Journal:  Bioorg Med Chem Lett       Date:  2011-06-06       Impact factor: 2.823

4.  In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.

Authors:  Michael J Pucci; Jijun Cheng; Steven D Podos; Christy L Thoma; Jane A Thanassi; Douglas D Buechter; Gohar Mushtaq; Gerald A Vigliotti; Barton J Bradbury; Milind Deshpande
Journal:  Antimicrob Agents Chemother       Date:  2007-01-22       Impact factor: 5.191

Review 5.  A "Double-Edged" Scaffold: Antitumor Power within the Antibacterial Quinolone.

Authors:  Gregory S Bisacchi; Michael R Hale
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

6.  In vitro activity of a new isothiazoloquinolone, ACH-702, against Mycobacterium tuberculosis and other mycobacteria.

Authors:  Carmen A Molina-Torres; Jorge Ocampo-Candiani; Adrian Rendón; Michael J Pucci; Lucio Vera-Cabrera
Journal:  Antimicrob Agents Chemother       Date:  2010-03-15       Impact factor: 5.191

7.  In vitro and in vivo profiles of ACH-702, an isothiazoloquinolone, against bacterial pathogens.

Authors:  Michael J Pucci; Steven D Podos; Jane A Thanassi; Melissa J Leggio; Barton J Bradbury; Milind Deshpande
Journal:  Antimicrob Agents Chemother       Date:  2011-04-04       Impact factor: 5.191

8.  Bactericidal activity of ACH-702 against nondividing and biofilm Staphylococci.

Authors:  Steven D Podos; Jane A Thanassi; Melissa Leggio; Michael J Pucci
Journal:  Antimicrob Agents Chemother       Date:  2012-04-30       Impact factor: 5.191

9.  Drug-resistant tuberculosis: emerging treatment options.

Authors:  Meghna Adhvaryu; Bhasker Vakharia
Journal:  Clin Pharmacol       Date:  2011-12-14

10.  Intracellular activity of tedizolid phosphate and ACH-702 versus Mycobacterium tuberculosis infected macrophages.

Authors:  Carmen A Molina-Torres; Alejandra Barba-Marines; Orestes Valles-Guerra; Jorge Ocampo-Candiani; Norma Cavazos-Rocha; Michael J Pucci; Jorge Castro-Garza; Lucio Vera-Cabrera
Journal:  Ann Clin Microbiol Antimicrob       Date:  2014-04-04       Impact factor: 3.944

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.